Drug Target Review rounds up some of the latest news in COVID-19 vaccine candidate R&D.
List view / Grid view
Filter the results
Drug Target Review explores some of the newest oncologic drug targets, including those for glioblastoma, lung cancer and breast cancer.
Dr Santosh Mishra and Srisruti Bontala explain how they discovered a new cutaneous-nerve pathway for allergic itch in atopic dermatitis.
Drug Target Review highlights five of the latest imaging advancements in the field of microscopy.
Which immune cells contribute towards immune-induced neurodegeneration and how could this knowledge enable conditions such Alzheimer’s and multiple sclerosis to be treated?
Researchers who developed a machine learning algorithm to predict the adverse effects of new drug compounds have released it as an open source tool.
This article outlines the ideal scientific research that should be conducted to design a prophylactic to combat COVID-19.
Researchers have found that a plasma exchange process can act as a molecular reset button for old blood, improving the health of ageing mice.
Phoebe Chubb explores how digitalisation is shaking up the world of drug discovery and development by increasing productivity and reducing human error.
Dr Ulrich Kutschera outlines why more studies are necessary before the spread and deadliness of the novel coronavirus is fully understood.
Rick Wagner of ZebiAI and Patrick Riley of Google Accelerated Science (GAS) discuss the development and benefits of a new machine learning drug discovery platform.
Dr Sarah Doyle and Dr Ema Ozaki outline their research into SARM1 and why it presents an attractive target for treating retinal degeneration.
Keith Murphy, CEO of Viscient Biosciences, discusses the process of developing a 3D bioprinted tissue model and their potential in developing therapeutics for COVID-19 and other diseases.
An analysis of papers relating to COVID-19 has found that female researchers make up a third of authors. Here, the potential reasons behind this figure are explored and a possible solution to encourage equality.
Dr Jing Watnick discusses how lessons learnt from cancer immunotherapy treatments could be applied to the development of COVID-19 therapies.